Melatonin jet lag and sleep onset, what the EU authorised

Anyone researching melatonin jet lag encounters extensive consumer guidance but very little discussion of the statutory rules governing European food labels. The wording permitted on packaging across the European Union is fixed by law. Two health claims for melatonin are authorised across the European Union and no others. One concerns the time taken to fall asleep, the other the subjective feelings of jet lag. Both appear in the Annex to Regulation (EU) No 432/2012, which is the consolidated list of permitted claims made on foods.

The authorised jet lag claim and its conditions

The second claim is worded as melatonin contributes to the alleviation of subjective feelings of jet lag. The word subjective is in the authorised wording and is not decoration; it marks what was assessed, which is how people reported feeling.

Its condition of use differs. The claim may be used only for a food containing at least 0,5 mg of melatonin per quantified portion, and the consumer must be told that the beneficial effect is obtained with a minimum intake of 0,5 mg taken close to bedtime on the first day of travel and on the following few days after arrival.

The sleep onset claim and packaging requirements

The first claim is worded, in the English text of the Annex, as melatonin contributes to the reduction of time taken to fall asleep. The wording is fixed by the regulation and a label may not improve on it.

CIBDOL · The sleep onset claim and packaging requirements

Its condition of use is exact. The claim may be used only for a food which contains 1 mg of melatonin per quantified portion, and the consumer must be told that the beneficial effect is obtained by consuming 1 mg close to bedtime.

Scientific opinions behind the wording

Both entries cite the scientific opinions they rest on, published in 2011 for the sleep onset claim and in 2010 for the jet lag claim. A claim on this list is not a marketing phrase that was allowed through; it is a wording that survived an assessment and was then fixed.

Unauthorised statements on food labels

Anything else said about melatonin on a food label is not authorised. The list is exhaustive for the substances on it, so a product may carry these two statements under their conditions and no other health claim about melatonin. Commercial descriptions that promise broader effects fall outside the authorised text.

Authorisation compared with measured effect size

An authorised claim states that a relationship was substantiated, not how large it is. The pooled clinical picture is modest: a meta-analysis of 19 randomised placebo-controlled trials covering 1683 participants found the time taken to fall asleep shortened by 7.06 minutes on average, with a 95 percent confidence interval of 4.37 to 9.75 minutes. ^[1]

Authorisation establishes that an effect was verified under regulatory standards, while clinical trials measure the scale of that effect in minutes. This article quotes a regulation as it stood on 13 September 2026. It is not legal advice.